The costs and inequities of precision medicine for patients with prostate cancer: A call to action. Read more about The costs and inequities of precision medicine for patients with prostate cancer: A call to action.
Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer. Read more about Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer.
Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention. Read more about Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention.
Is a restaging TURBT necessary in high-risk NMIBC if the initial TURBT was performed with blue light? Read more about Is a restaging TURBT necessary in high-risk NMIBC if the initial TURBT was performed with blue light?
Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers. Read more about Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma. Read more about Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma.
Medium Term Outcomes of Focal Cryoablation for Intermediate and High Risk Prostate Cancer: MRI and PSA are Not Predictive of Residual or Recurrent Disease. Read more about Medium Term Outcomes of Focal Cryoablation for Intermediate and High Risk Prostate Cancer: MRI and PSA are Not Predictive of Residual or Recurrent Disease.
Patient engagement in a mobile health intervention to improve preparedness for prostate biopsy. Read more about Patient engagement in a mobile health intervention to improve preparedness for prostate biopsy.
Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset. Read more about Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset.
Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy. Read more about Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy.
